You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 9,186,339

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,186,339

Title:	Use of transcriptome modifying agents and chemotherapy or radiotherapy against cancer
Abstract:	The use of transcriptome-modifying agents is disclosed in order to prevent malignant cells from undergoing the necessary genetic changes in order to combat cell insult and survive chemotherapy or radiotherapy. The combination of transcriptome-modifying agents comprises agents that inhibit the DNA methylation machinery plus a substance that inhibits histone deacetylation. A treatment kit is disclosed which includes an effective dose of hydralazine and valproic acid or a salt of same in the case of magnesium valproate, which is intended for use with radiotherapy or chemotherapy in the treatment of patients cancer.
Inventor(s):	Gonzalez; Alfonso Duenas (Mexico D.F., MX), Flores; Luis Estrada (Col. Torielo Guerra, MX)
Assignee:	UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO (Mexico, C.P., Mexico City, unknown) PSICOFARMA, S.A. DE C.V. (Colonia Toriello Guerra, C.P., Mexico City, unknown)
Application Number:	12/093,906
Patent Claims:	1. A pharmaceutical composition comprising: hydralazine present in an amount selected from the group consisting of about 83 mg for individuals exhibiting slow acetylation and about 182 mg for individuals exhibiting fast acetylation; valproic acid or a salt thereof present in an amount of about 30 mg/kg; wherein the hydralazine and the valproic acid or the salt thereof are combined with a pharmaceutically acceptable vehicle for treating cancer. 2. The pharmaceutical composition according to claim 1, wherein the salt of the valproic acid is magnesium valproate. 3. A method treating cancer, the method comprising: administering the pharmaceutical composition of claim 1 to a patient in need of cancer treatment; wherein the administering is performed to assist in the treatment of cancer together with chemotherapy or radiotherapy. 4. The method according to claim 3, wherein the chemotherapeutic agent is selected from the group consisting of: chlorambucil; cyclophosphamide; iphosphamide; mechlorethamine; melphalan thiotepa; carmustine; lomustine; altretamine; dacarbazine; procarbazine; cisplatin; carboplastin; oxaliplatin; doxorubicin; daunorubicin; epirubicin; idarubicin; mitomycin C; bleomycin; dactinomycin; retinoids; vincristine; vinblastine; vindesine; vinorelbine; irinotecan; topotecan; etoposide; teniposide; paclitaxel; docetaxel; 5-fluorouracil; gemcitabine; methotrexate; interleukins; interferons; trastuzumab; cetuximab; rituxan; myelotarg; gefitinib; erlotinib; and imatinib. 5. The method of claim 3, wherein said cancer is selected from the group consisting of: breast; ovary; uterine; skin; bone; prostate; liver; kidney; lung; brain; gall bladder; pancreas; colon; rectum; parathyroid; thyroid; adrenal; stomach; kidney; pheochromocytoma; Wilms tumor; testicle; cervicouterine; nueroblastoma; sarcoma; leukemia; lymphoma; and myelodysplasic syndromes. 6. The method according to claim 3, wherein the salt of valproic acid is magnesium valproate. 7. The method according to claim 3, further comprising administering the pharmaceutical composition orally and daily.

Details for Patent 9,186,339

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2039-02-26
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2039-02-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2039-02-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.